Why Surface Oncology Is Flying Higher After Hours Today

Regulatory approvals are big wins for biotech companies. It is no different for cancer drug specialist Surface Oncology (NASDAQ:SURF), the shares of which were up nearly 13% in early after-hours trading Tuesday following an important nod from the U.S. Food and Drug Administration (FDA).